Here’s what you should know:
1. The FTC cleared the acquisition unconditionally.
2. The deal still has a number of regulatory burdens to clear and needs shareholder approval.
3. If Takeda completes the deal, it will be the world’s most indebted drugmaker. To ease the burden, the company has made a series of transactions, including listing its Osaka, Japan-based headquarters for sale.
4. If the deal receives all necessary approvals, it could close in the first half of 2019.
More articles on supply chain:
Joint replacement, spine ASC opens in Southern California
Dr. Paul Chin becomes 1st surgeon in Texas to use Catalyst Orthoscience device: 5 takeaways
5 organizations teaming up to tackle antibiotic resistance in outpatient space— 5 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.